Hanes, R. | bioRxiv Science

bioRxiv2022

metascreen: A modular tool for the design and analysis of drug combination screens

There is a rapidly growing interest in high-throughput drug combination screening to identify synergizing drug interactions for treatment of various maladies, such as cancer and infectious disease. This creates the need for pipelines that can be used to design such screens, perform quality control on the data, and generate data files that can be analyzed by synergy-finding bioinformatics applications. metascreen is an open source, end-to-end modular tool available as an R-package for the design and analysis of drug combination screens. The tool allows for a customized build of pipelines through its modularity and provides a flexible approach to quality control and data analysis. metascreen is adaptable to various experimental requirements with an emphasis on precision medicine. It can be coupled to other R packages, such as bayesynergy, to identify synergistic and antagonistic drug interactions in cell lines or patient samples. metascreen is scalable and provides a complete solution for setting up drug sensitivity screens, read raw measurements and consolidate different datasets, perform various types of quality control, and analyze, report and visualize the results of drug sensitivity screens. Availability and implementationThe R-package and technical documentation is available at https://github.com/Enserink-lab; the R source code is publicly available at https://github.com/Enserink-lab/metascreen under GNU General Public License v3.0; bayesynergy is accessible at https://github.com/ocbe-uio/bayesynergy/ Selected modules will be available through Galaxy, an open-source platform for FAIR data analysis, Norway: https://usegalaxy.no

bioinformatics↗

bioRxiv2021

bayesynergy: flexible Bayesian modelling of synergistic interaction effects in in-vitro drug combination experiments

The effect of cancer therapies is often tested pre-clinically via in-vitro experiments, where the post-treatment viability of the cancer cell population is measured through assays estimating the number of viable cells. In this way, large libraries of compounds can be tested, comparing the efficacy of each treatment. Drug interaction studies focus on the quantification of the additional effect encountered when two drugs are combined, as opposed to using the treatments separately. In the bayesynergy R package, we implement a probabilistic approach for the description of the drug combination experiment, where the observed dose response curve is modelled as a sum of the expected response under a zero-interaction model and an additional interaction effect (synergistic or antagonistic). The interaction is modelled in a flexible manner, using a Gaussian process formulation. Since the proposed approach is based on a statistical model, it allows the natural inclusion of replicates, handles missing data and uneven concentration grids, and provides uncertainty quantification around the results. The model is implemented in the Stan programming language providing a computationally efficient sampler, a fast approximation of the posterior through variational inference, and features parallel processing for working with large drug combination screens.

bioinformatics↗